Foghorn Therapeutics (FHTX) EPS (Weighted Average and Diluted) (2020 - 2025)
Historic EPS (Weighted Average and Diluted) for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to -$0.25.
- Foghorn Therapeutics' EPS (Weighted Average and Diluted) rose 1935.48% to -$0.25 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.13, marking a year-over-year increase of 4114.58%. This contributed to the annual value of -$1.58 for FY2024, which is 3257.29% up from last year.
- Latest data reveals that Foghorn Therapeutics reported EPS (Weighted Average and Diluted) of -$0.25 as of Q3 2025, which was up 1935.48% from -$0.28 recorded in Q2 2025.
- Over the past 5 years, Foghorn Therapeutics' EPS (Weighted Average and Diluted) peaked at -$0.25 during Q3 2025, and registered a low of -$0.77 during Q4 2021.
- Over the past 5 years, Foghorn Therapeutics' median EPS (Weighted Average and Diluted) value was -$0.62 (recorded in 2021), while the average stood at -$0.54.
- Examining YoY changes over the last 5 years, Foghorn Therapeutics' EPS (Weighted Average and Diluted) showed a top increase of 7827.59% in 2021 and a maximum decrease of 13043.48% in 2021.
- Over the past 5 years, Foghorn Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.77 in 2021, then increased by 10.39% to -$0.69 in 2022, then increased by 17.39% to -$0.57 in 2023, then surged by 37.68% to -$0.36 in 2024, then grew by 29.63% to -$0.25 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.25 for Q3 2025, versus -$0.28 for Q2 2025 and -$0.3 for Q1 2025.